Geode Capital Management LLC Has $779.86 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Geode Capital Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,398,770 shares of the biopharmaceutical company’s stock after buying an additional 75,936 shares during the period. Geode Capital Management LLC owned 1.83% of Alnylam Pharmaceuticals worth $779,857,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Bayforest Capital Ltd lifted its holdings in Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 39 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Alnylam Pharmaceuticals by 32.6% in the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. PNC Financial Services Group Inc. now owns 13,170 shares of the biopharmaceutical company’s stock valued at $4,295,000 after purchasing an additional 45 shares during the period. Fulton Bank N.A. lifted its stake in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 46 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 49 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Piper Sandler reiterated an “overweight” rating and issued a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. UBS Group boosted their price objective on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, August 1st. BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $453.97 on Friday. The company has a market cap of $59.98 billion, a price-to-earnings ratio of -183.79 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a fifty day moving average price of $458.86 and a 200-day moving average price of $381.74.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 66,696 shares of company stock valued at $30,430,694 over the last three months. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.